Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression

Journal of Neurogenetics

Volumn 25, Issue 4, 2011, Pages 152-166

  Campo, Brice ^a   Kalinichev, Mikhail ^a   Lambeng, Nathalie ^a   Yacoubi, M El ^b,c   Royer Urios, Isabelle ^a   Schneider, Manfred ^a   Legrand, Coline ^a   Parron, Delphine ^a   Girard, Francoise ^a   Bessif, Abdelhak ^a   Poli, Sonia ^a   Vaugeois, Jean Marie ^b,c,d   Poul, Emmanuel Le ^a   Celanire, Sylvain ^a  

^a ADDEX PHARMACEUTICALS   (Switzerland)

^b LYON NEUROSCIENCE RESEARCH CENTER   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITÉ DE ROUEN   (France)

Author keywords

Animal model; Depression; Metabotropic glutamate receptor

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 [ 3 ( 2,6 DIMETHYLPYRIDIN 4 YL)PHENYL] 7 METHYL 8 TRIFLUOROMETHYL 1,3 DIHYDROBENZO[B][ 1, 4 ]DIAZEPIN 2 ONE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; BACLOFEN; CALCIUM ION; DIAZEPINE DERIVATIVE; GLUTAMIC ACID; GUANOSINE TRIPHOSPHATE; IMIPRAMINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR ANTAGONIST; RO 4491533; SULFUR 35; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; BRAIN; CALCIUM MOBILIZATION; CELL MEMBRANE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TARGETING; EXPERIMENTAL TEST; FEEDING; FORCED SWIMMING TEST; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMOBILIZATION; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; RODENT; TAIL SUSPENSION TEST; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALLOSTERIC REGULATION; ANIMALS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; BENZODIAZEPINONES; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE;

ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 81555205690     PISSN: 01677063     EISSN: 15635260     Source Type: Journal    
DOI: 10.3109/01677063.2011.627485     Document Type: Article

References (60)

1. Ballard, T. M., Gatti Mcarthur, S., Goetschi, E., Wichmann, J., & Woltering, T. J. (2005). Patent No. WO 2005/014002 . F. Hoffmann-La Roche AG.
2. Battaglia, G., Molinaro, G., Riozzi, B., Storto, M., Busceti, C. L., Spinsanti, P., Bucci, D., Di, L., V, Mudo, G., Corti, C., Corsi, M., Nicoletti, F., Belluardo, N., & Bruno, V. (2009). Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons. PLoS ONE, 4, e6591.
3. Bespalov, A. Y., van Gaalen, M. M., Sukhotina, I. A., Wicke, K., Mezler, M., Schoemaker, H., & Gross, G. (2008). Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur J Pharmacol, 592, 96-102.
4. Caraci, F., Molinaro, G., Battaglia, G., Giuffrida, M. L., Riozzi, B., Trafi cante, A., Bruno, V., Cannella, M., Merlo, S., Wang, X., Heinz, B. A., Nisenbaum, E. S., Britton, T. C., Drago, F., Sortino, M. A., Copani, A., & Nicoletti, F. (2011). Targeting group ii metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with alzheimer's disease: Selective activation of mglu2 receptors amplifi es â-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol Pharmacol , 79, 618-626.
5. Cartmell, J., & Schoepp, D. D. (2000). Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem , 75, 889-907.
6. Chaki, S., Yoshikawa, R., Hirota, S., Shimazaki, T., Maeda, M., Kawashima, N., Yoshimizu, T., Yasuhara, A., Sakagami, K., Okuyama, S., Nakanishi, S., & Nakazato, A. (2004). MGS0039: A potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology , 46, 457-467.
7. Chan, W. Y., McKinzie, D. L., Bose, S., Mitchell, S. N., Witkin, J. M., Thompson, R. C., Christopoulos, A., Lazareno, S., Birdsall, N. J., Bymaster, F. P., & Felder, C. C. (2008). Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci U S A , 105, 10978-10983.
8. Christopoulos, A., & Kenakin, T. (2002). G Protein-coupled receptor allosterism and complexing. Pharmacol Rev , 54, 323-374.
9. Ciccarelli, R., D'Alimonte, I., Ballerini, P., D'Auro, M., Nargi, E., Buccella, S., Di, I. P., Bruno, V., Nicoletti, F., & Caciagli, F. (2007). Molecular signalling mediating the protective effect of A1 adenosine and mGlu3 metabotropic glutamate receptor activation against apoptosis by oxygen/glucose deprivation in cultured astrocytes. Mol Pharmacol , 71, 1369-1380.
10. Clinton, S. M., Haroutunian, V., Davis, K. L., & Meador- Woodruff, J. H. (2003). Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry , 160, 1100-1109.
11. Conn, P. J., Christopoulos, A., & Lindsley, C. W. (2009). Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat Rev Drug Discov , 8, 41-54.
12. Danysz, W., Zajaczkowski, W., & Parsons, C. G. (1995). Modulation of learning processes by ionotropic glutamate receptor ligands. Behav Pharmacol , 6, 455-474.
13. Ehlert, F. J. (2005). Analysis of allosterism in functional assays. J Pharmacol Exp Ther , 315, 740-754.
14. El Yacoubi, M., Bouali, S., Popa, D., Naudon, L., Leroux-Nicollet, I., Hamon, M., Costentin, J., Adrien, J., & Vaugeois, J. M. (2003). Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl Acad Sci U S A , 100, 6227-6232.
15. Feyissa, A. M., Woolverton, W. L., Miguel-Hidalgo, J. J., Wang, Z., Kyle, P. B., Hasler, G., Stockmeier, C. A., Iyo, A. H., & Karolewicz, B. (2010). Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry , 34, 279-283.
16. Hashimoto, K. (2009). Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev , 61, 105-123.
17. Higgins, G. A., Ballard, T. M., Kew, J. N., Richards, J. G., Kemp, J. A., Adam, G., Woltering, T., Nakanishi, S., & Mutel, V. (2004). Pharmacological manipulation of mGlu2 receptors infl uences cognitive performance in the rodent. Neuropharmacology , 46, 907-917.
18. Johnson, B. G., Wright, R. A., Arnold, M. B., Wheeler, W. J., Ornstein, P. L., & Schoepp, D. D. (1999). [ 3 H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: Characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology , 38, 1519-1529.
19. Kalinichev, M., Bate, S. T., Coggon, S. A., & Jones, D. N. (2008). Locomotor reactivity to a novel environment and sensitivity to MK-801 in fi ve strains of mice. Behav Pharmacol , 19, 71-75.
20. Kalinichev, M., Campo, B., Lambeng, N., Célanire, S., Schneider, M., Bessif, A., Royer-Urios, I., Parron, D., Legrand, C., Mahious, N., Girard, F., & Le Poul, E. (2010). AN mGluR2/3 negative allosteric modulator improves recognition memory assessedby natural forgetting in the novel object recognition test in rats.
21. Karasawa, J., Shimazaki, T., Kawashima, N., & Chaki, S. (2005). AMPA receptor stimulation mediates the antidepressantlike effect of a group II metabotropic glutamate receptor antagonist. Brain Res , 1042, 92-98.
22. Kawashima, N., Karasawa, J., Shimazaki, T., Chaki, S., Okuyama, S., Yasuhara, A., & Nakazato, A. (2005). Neuropharmacological profi les of antagonists of group II metabotropic glutamate receptors. Neurosci Lett , 378, 131-134.
23. Kenakin, T. (2004). Allosteric modulators: The new generation of receptor antagonist. Mol Interv , 4, 222-229.
24. Kenakin, T. (2005). New concepts in drug discovery: Collateral effi cacy and permissive antagonism. Nat Rev Drug Discov , 4, 919-927.
25. Kenakin, T. (2007). Collateral effi cacy in drug discovery: Taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci , 28, 407-415.
26. Kew, J. N. (2004). Positive and negative allosteric modulation of metabotropic glutamate receptors: Emerging therapeutic potential. Pharmacol Ther , 104, 233-244.
27. Kim, S. H., Fraser, P. E., Westaway, D., St George-Hyslop, P. H., Ehrlich, M. E., & Gandy, S. (2010). Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals. J Neurosci , 30, 3870-3875.
28. Kingston, A. E., Ornstein, P. L., Wright, R. A., Johnson, B. G., Mayne, N. G., Burnett, J. P., Belagaje, R., Wu, S., & Schoepp, D. D. (1998). LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology , 37, 1-12.
29. Knofl ach, F., Ballard, T., Goetschi, E., Wichmann, J., Woltering, T., & Gatti, S. (2005). R1315, a potent orally active noncompetitive group II metabotropic glutamate receptor antagonist with cognitive enhancing properties.
30. Lambeng, N., Campo, B., Kalinichev, M., Célanire, S., Tang, L., Da Silva, J., Fonteny, F., Gagliardi, S., Rencurosi, A., Schneider, M., Royer-Urios, I., Mingard, B., Pastor, F., Girard, F., Bessif, A., Legrand, C., & Le Poul, E. (2010). Selective mGluR2 negative allosteric modulators reverse the scopolamine-induced memory defi cit in the novel object recognition test.
31. Lazareno, S., & Birdsall, N. J. (1995). Detection, quantitation, and verifi cation of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol , 48, 362-378.
32. May, L. T., Leach, K., Sexton, P. M., & Christopoulos, A. (2007). Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol , 47, 1-51.
33. McCullumsmith, R. E., & Meador-Woodruff, J. H. (2002). Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology , 26, 368-375.
34. Monn, J. A., Valli, M. J., Massey, S. M., Hansen, M. M., Kress, T. J., Wepsiec, J. P., Harkness, A. R., Grutsch, J. L., Jr., Wright, R. A., Johnson, B. G., Andis, S. L., Kingston, A., Tomlinson, R., Lewis, R., Griffey, K. R., Tizzano, J. P., & Schoepp, D. D. (1999). Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to + -2-aminobicyclo[3.1.0] hexane- 2,6-dicarboxylic acid (LY354740): Identifi cation of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem , 42, 1027-1040.
35. Murakami, H., Takanaga, H., Matsuo, H., Ohtani, H., & Sawada, Y. (2000). Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am J Physiol Heart Circ Physiol , 279, H1022-H1028.
36. Nakanishi, S., Nakajima, Y., Masu, M., Ueda, Y., Nakahara, K., Watanabe, D., Yamaguchi, S., Kawabata, S., & Okada, M. (1998). Glutamate receptors: Brain function and signal transduction. Brain Res Brain Res Rev , 26, 230-235.
37. Nestler, E. J., Barrot, M., Dileone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002). Neurobiology of depression. Neuron , 34, 13-25.
38. Niswender, C. M., Johnson, K. A., Miller, N. R., Ayala, J. E., Luo, Q., Williams, R., Saleh, S., Orton, D., Weaver, C. D., & Conn, P. J. (2010). Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol Pharmacol , 77, 459-468.
39. Ornstein, P. L., Bleisch, T. J., Arnold, M. B., Wright, R. A., Johnson, B. G., & Schoepp, D. D. (1998). 2-Substituted (2 SR )-2-amino- 2-((1 SR ,2 SR )-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution. J Med Chem , 41, 346-357.
40. Palucha, A., & Pilc, A. (2005). The involvement of glutamate in the pathophysiology of depression. Drug News Perspect , 18, 262-268.
41. Paul, I. A., & Skolnick, P. (2003). Glutamate and depression: Clinical and preclinical studies. Ann N Y Acad Sci , 1003, 250-272.
42. Petrie, R. X., Reid, I. C., & Stewart, C. A. (2000). The N -methyl- daspartate receptor, synaptic plasticity, and depressive disorder. A critical review. Pharmacol Ther , 87, 11-25.
43. Popa, D., El, Y. M., Vaugeois, J. M., Hamon, M., & Adrien, J. (2006). Homeostatic regulation of sleep in a genetic model of depression in the mouse: Effects of muscarinic and 5-HT 1A receptor activation. Neuropsychopharmacology , 31, 1637-1646.
44. Rosenberg, D. R., MacMaster, F. P., Keshavan, M. S., Fitzgerald, K. D., Stewart, C. M., & Moore, G. J. (2000). Decrease in caudate glutamatergic concentrations in pediatric obsessivecompulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry , 39, 1096-1103.
45. Schechter, L. E., Ring, R. H., Beyer, C. E., Hughes, Z. A., Khawaja, X., Malberg, J. E., & Rosenzweig-Lipson, S. (2005). Innovative approaches for the development of antidepressant drugs: Current and future strategies. NeuroRx , 2, 590-611.
46. Schoepp, D. D., Jane, D. E., & Monn, J. A. (1999). Pharmacological agents acting at subtypes of meta botropic glutamate receptors. Neuropharmacology , 38, 1431-1476.
47. Shimazaki, T., Kaku, A., & Chaki, S. (2007). Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats. Eur J Pharmacol , 575, 94-97.
48. Skolnick, P., Popik, P., & Trullas, R. (2009). Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci , 30, 563-569.
49. Spinelli, S., Ballard, T., Gatti-McArthur, S., Richards, G. J., Kapps, M., Woltering, T., Wichmann, J., Stadler, H., Feldon, J., & Pryce, C. R. (2005). Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys. Psychopharmacology , 179, 292-302.
50. Spooren, W. P., Gasparini, F., Van der, P. H., Koller, M., Nakanishi, S., & Kuhn, R. (2000). Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur J Pharmacol , 397, R1-R2.
51. Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000). Genetic epidemiology of major depression: Review and metaanalysis. Am J Psychiatry , 157, 1552-1562.
52. Taylor, D. L., Diemel, L. T., & Pocock, J. M. (2003). Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J Neurosci , 23, 2150-2160.
53. Turri, M. G., Datta, S. R., DeFries, J., Henderson, N. D., & Flint, J. (2001). QTL analysis identifi es multiple behavioral dimensions in ethological tests of anxiety in laboratory mice. Curr Biol , 11, 725-734.
54. Woltering, T. J., Wichmann, J., Goetschi, E., Knofl ach, F., Ballard, T. M., Huwyler, J., & Gatti, S. (2010). Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin- 2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists. Bioorg Med Chem Lett , 20, 6969-6974.
55. Woolley, M. L., Pemberton, D. J., Bate, S., Corti, C., & Jones, D. N. (2008). The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology , 196, 431-440.
56. Wright, R. A., Arnold, M. B., Wheeler, W. J., Ornstein, P. L., & Schoepp, D. D. (2000). Binding of [ 3 H](2 S ,1' S ,2' S )-2- (9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([ 3 H] LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn-Schmiedeberg Arch Pharmacol , 362, 546-554.
57. Wright, R. A., Arnold, M. B., Wheeler, W. J., Ornstein, P. L., & Schoepp, D. D. (2001). [ 3 H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. J Pharmacol Exp Ther , 298, 453-460.
58. Yoshikawa, T., Watanabe, A., Ishitsuka, Y., Nakaya, A., & Nakatani, N. (2002). Identifi cation of multiple genetic loci linked to the propensity for "behavioral despair" in mice. Genome Res , 12, 357-366.
59. Yoshimizu, T., Shimazaki, T., Ito, A., & Chaki, S. (2006). An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology , 186, 587-593.
60. Zwienenberg, M., Gong, Q. Z., Berman, R. F., Muizelaar, J. P., & Lyeth, B. G. (2001). The effect of groups II and III metabotropic glutamate receptor activation on neuronal injury in a rodent model of traumatic brain injury. Neurosurgery , 48, 1119-1126.